Datadog went public on Thursday and instantly hit a $10 billion valuation, becoming the fourth cloud software debut to reach that level this year.Technologyread more
Blackstone Executive Vice Chairman Tony James says he's less optimistic now than before that the U.S.-China trade war could be resolved, but even a smaller deal could help...World Economyread more
There are challenges with Iran, North Korea, the Afghan Taliban, Israel and the Palestinians — not to mention a number of trade pacts.Politicsread more
In perhaps Buffett's first televised profile, he explained a method of investing that prioritizes bargains and makes use of an occasional baseball analogy.Marketsread more
The massive market transformation this month that some on Wall Street called a "once in a decade opportunity" might have just been a one-off technical move because of taxes.Marketsread more
A 58% majority of registered voters express unease about voting for Trump, but slightly more say the same about Joe Biden and Bernie Sanders, while Elizabeth Warren fares only...Politicsread more
A temporary airspace closure forced flights coming into Dubai from Australia, Singapore and India to be diverted to nearby airports.Airlinesread more
As the home to major companies such as Garmin, Sprint, H&R Block and Russell Stover Chocolates, plenty of business travelers find themselves in Kansas City for work. Here's...Travelread more
Investors are asking how the world's third-largest defense spender could have left itself so vulnerable and what that means for the future.Politicsread more
The Pentagon will deploy U.S. forces to the Middle East on the heels of the attack on Saudi Arabian oil facilities, United States Secretary of Defense Mark Esper announced...Defenseread more
Solar power is on the rise. You can see the evidence on rooftops and in the desert, where utility-scale solar plants are popping up. The picture is not all rosy, but if the...Technologyread more
Medicines in development at Biogen and Eli Lilly could be the first to slow the cognitive declines brought by Alzheimer's disease. New data will be presented Wednesday at the Alzheimer's Association International Conference in Washington, D.C. So how do they work?
The drugs take aim at the plaque buildups in the brain that characterize Alzheimer's, known as beta amyloid. Unlike currently marketed drugs Aricept and Namenda, which affect levels of certain brain chemicals and may temporarily ease symptoms of Alzheimer's, Biogen's and Lilly's drugs may be disease modifying.
Read More The next trigger for Biogen shares
They're important because they have instilled new confidence in what's known as the amyloid hypothesis: the idea that targeting those plaque buildups will actually slow the disease.
The medicines bind to beta amyloid in slightly different ways, but both companies are treating patients in the earlier stages of Alzheimer's disease. It's thought that additional methods will be needed to help patients who have cases that are more advanced.
Other approaches include targeting tangles of proteins known as tau, and reducing the production of beta amyloid in the first place by inhibiting an enzyme known as beta secretase.
Read MoreBreakthrough in Parkinson's